Core Outcome Set for GROwth restriction: deVeloping Endpoints (COSGROVE)
dc.contributor.author | Healy, Patricia | |
dc.contributor.author | Gordijn, Sanne | |
dc.contributor.author | Ganzevoort, Wessel | |
dc.contributor.author | Beune, Irene | |
dc.contributor.author | Baschat, Ahmet | |
dc.contributor.author | Khalil, Asma | |
dc.contributor.author | Kenny, Louise C. | |
dc.contributor.author | Bloomfield, Frank | |
dc.contributor.author | Daly, Mandy | |
dc.contributor.author | Papageorghiou, Aris | |
dc.contributor.author | Devane, Declan | |
dc.contributor.funder | Health Research Board, Ireland | en |
dc.date.accessioned | 2019-11-25T10:38:01Z | |
dc.date.available | 2019-11-25T10:38:01Z | |
dc.date.issued | 2018-08-22 | |
dc.description.abstract | Foetal growth restriction (FGR) refers to a foetus that does not reach its genetically predetermined growth potential. It is well recognised that growth-restricted foetuses are at increased risk of stillbirth, foetal compromise, early neonatal death and neonatal morbidity. Later in life, they are prone to health problems, including increased risk of cardiovascular diseases and neurodevelopmental disorders. Interventions for preventing and treating FGR have been studied in many trials, but evidence is often difficult to synthesise and compare because of differences in the selection and definition of outcomes. To enable future trials to measure similar, meaningful outcomes, we are developing two core outcome sets (COS) – one for prevention and the other for treatment of FGR. | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Published Version | en |
dc.format.mimetype | application/pdf | en |
dc.identifier.articleid | 451 | en |
dc.identifier.citation | Healy, P., Gordijn, S., Ganzevoort, W., Beune, I., Baschat, A., Khalil, A., Kenny, L., Bloomfield, F., Daly, M., Papageorghiou, A. and Devane, D., 2018. Core Outcome Set for GROwth restriction: deVeloping Endpoints (COSGROVE). Trials, 19(1), (451). DOI: 10.1186/s13063-018-2819-9 | en |
dc.identifier.doi | 10.1186/s13063-018-2819-9 | en |
dc.identifier.eissn | 1745-6215 | |
dc.identifier.endpage | 7 | en |
dc.identifier.issued | 1 | en |
dc.identifier.journaltitle | Trials | en |
dc.identifier.startpage | 1 | en |
dc.identifier.uri | https://hdl.handle.net/10468/9211 | |
dc.identifier.volume | 19 | en |
dc.language.iso | en | en |
dc.publisher | BioMed Central | en |
dc.relation.uri | https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-018-2819-9 | |
dc.rights | © The Author(s) 2018 | en |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | en |
dc.subject | Core outcome sets | en |
dc.subject | Delphi | en |
dc.subject | Methodology | en |
dc.subject | Foetal growth restriction | en |
dc.subject | Pregnancy | en |
dc.title | Core Outcome Set for GROwth restriction: deVeloping Endpoints (COSGROVE) | en |
dc.type | Article (peer-reviewed) | en |